Tanabe Seiyaku Company, Limited

Mitsubishi Tanabe Pharma Corporation

Masataka Hikota

Kenji Arakawa

Kosuke Yasuda

Takeshi Matsumoto

Hiroshi Morimoto

Saburo Kawanami

Koichiro Yamada

Masaaki Nagasaki

Toshiro Shikano

Naoyuki Harada

Kenji Omori

Kohei Kikkawa

Yuichi Koga

Takeshi Yura

Norvaline derivative of the formula [I] or pharmaceutically acceptable salt thereof, method for preparing the same, pharmaceutical composition containing the same, and use of the compound for inhibiting transporting activity of glycine transporter type 2 (GlyT2)  

Norvaline derivative and method for preparation thereof

The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: 

Nitrogen-containing 5-membered ring compound

The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: wherein symbols in the formula have the following meanings;

Aliphatic nitrogen-containing 5-membered ring compound

Nitrogenous 5-membered ring compounds

A pyridopyrimidine or a naphthyridine derivative of the formula (I): wherein Ris an optionally substituted nitrogen-containing heterocyclic group, etc.; Ris H or a lower alkyl group; Ris H or an optionally substituted lower alkyl group, etc.; Ris H, a lower alkyl group, COOH, etc.; Ris a lower alkyl group which may optionally be substituted by an optionally substituted aryl etc.; one of X and Y is CH and the other is nitrogen, or both of X and Y are nitrogen; or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent PDE V inhibitory activities, and being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.

Pyridopyrimidine or naphthyridine derivative

The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:wherein

Aliphatic nitrogenous five-membered ring compounds

2-oxoindoline derivative

Disclosed are .beta.-carboline derivatives represented by the formula: ##STR1## wherein R.sup.1 represents hydrogen atom, a lower alkyl group, a lower alkoxy group or hydroxy group; R.sup.5 represents hydrogen atom, or R.sup.1 and R.sup.5 are bonded to represent a lower alkylenedioxy group; R.sup.2 represents hydrogen atom, a halogen atom, a lower alkoxy group or hydroxy group; R.sup.3 represents hydrogen atom, a carbamoyl lower alkyl group, a lower alkyl group, a carboxy lower alkyl group or a lower alkoxycarbonyl lower alkyl group; R.sup.4 represents hydrogen atom, a lower alkyl group, a carboxy lower alkyl group, a lower alkoxycarbonyl lower alkyl group, a lower alkanoyl group, an arylcarbonyl group, a lower alkanesulfonyl group, a lower alkoxycarbonyl group, an aralkyl group, formyl group or a di(lower alkyl)sulfamoyl group; n represents 0, 1 or 2; and the symbol * represents an asymmetric carbon atom, or a pharmaceutically acceptable salt thereof, and a process for preparing the same.

.beta.-carboline derivative

Growing community of inventors

Shiki, Japan

Masataka Hikota